Stockreport

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focus [Read more]